Table 3.

Comparison between edematous myositis and idiopathic inflammatory myositis without edema

Variables	Non‐edematous IIM*	Edematous myositis	P‐value**
Age at diagnosis	46 [33.2; 58.7]	52 [45.2; 58.66]	1
Women	117 (67.2%)	10 (58.8%)	1
CK level (UI/L)	5000 [1710; 10372.7]	5118 [1654; 6928]	1
Muscle weakness	154 (88.5%)	15 (88.2%)	1
Dysphagia	82 (47.4%)	12 (70.6%)	1
Cancer	25 (14.4%)	4 (25%)	1
Raynaud	46 (26.74%)	2 (11.8%)	1
Arthritis	36 (21.6%)	0 (0%)	1
Capillary C5b‐9 deposition	47 (37%)	13 (92.9%)	0.003
MCH class 1 expression	106 (85.5%)	14 (100%)	1
DM skin rash	52 (29.9 %)	9 (52.9 %)	1
Interstitial lung disease	74 (44.6%)	1 (5.9%)	0.07
MSA
DM‐specific			<0.00001
MDA5	7 (4%)	0 (0%)
Mi‐2	12 (6.9%)	1 (5.9%)
NXP2	3 (1.7%)	2 (11.8%)
NXP2‐SAE	0 (0%)	1 (5.9%)
SAE	2 (1.1%)	1 (5.9%)
TIF1γ	3 (1.7%)	3 (17.6%)
IMNM‐specific
HMGCR	31 (17.8%)	0 (0%)
SPR	34 (19.5%)	0 (0%)
ASyS
Jo1	39 (22.4%)	0 (0%)
PL‐12	3 (1.7%)	0 (0%)
PL‐7	5 (2.9%)	0 (0%)
Seronegative	35 (20.1%)	7 (41.2%)
Not done	0 (0%)	2 (11.8%)	<0.00001

Abbreviations: DM = dermatomyositis; IMNM = immune mediated necrotizing myositis; IIM = idiopathic inflammatory myositis; MSA = myositis specific antibodies; ASyS = antisynthetase syndrome.

^*n (%) or median [Q1; Q3].

^**Adjusted P‐value Benjamini Hochberg.